Assignee
SHENZHEN SALUBRIS PHARM CO LTD
CN·8 granted patents·9 pending applications·1 citations·filing 2014–2025
Top patents by PatentIndex Score
17 records- 0171US10513514B2Piperidine compounds as PCSK9 inhibitorsSHENZHEN SALUBRIS PHARM CO LTD·Filed 2018·Granted Dec 24, 2019·1 cites·28 claims
- 0255US2024166627A1Terpyridinedione compound or salt thereof, and preparation method and application thereofSHENZHEN SALUBRIS PHARM CO LTD·Filed 2023·Application pending·0 cites
- 0354US2024246959A1Benzimidazole derivative and preparation method therefor and medical use thereofSHENZHEN SALUBRIS PHARM CO LTD·Filed 2021·Application pending·0 cites
- 0449US12453719B2Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitorSHENZHEN SALUBRIS PHARM CO LTD·Filed 2020·Granted Oct 28, 2025·0 cites·13 claims
- 0548US2023027295A1Fxia inhibitors and preparation method therefor and pharmaceutical use thereofSHENZHEN SALUBRIS PHARM CO LTD·Filed 2020·Application pending·0 cites
- 0647US11957758B2Pharmaceutical composition of docetaxel conjugate and preparation methodSHENZHEN SALUBRIS PHARM CO LTD·Filed 2018·Granted Apr 16, 2024·0 cites·13 claims
- 0745US9815848B2Method for preparing spherical Clopidogrel Hydrogen Sulfate polymorph ISHENZHEN SALUBRIS PHARM CO LTD·Filed 2014·Granted Nov 14, 2017·0 cites·10 claims
- 0842US2025320198A1Salt of endothelin a (eta) receptor antagonist compound, and preparation method therefor and medical use thereofSHENZHEN SALUBRIS PHARM CO LTD·Filed 2025·Application pending·0 cites
- 0939US11026925B2Angiotensin II receptor antagonist metabolite and NEP inhibitor composite and preparation method thereofSHENZHEN SALUBRIS PHARM CO LTD·Filed 2017·Granted Jun 8, 2021·0 cites·22 claims
- 1039US9670184B2Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxilSHENZHEN SALUBRIS PHARM CO LTD·Filed 2014·Granted Jun 6, 2017·0 cites·15 claims
- 1135US12508246B2Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failureSHENZHEN SALUBRIS PHARM CO LTD·Filed 2020·Granted Dec 30, 2025·0 cites·11 claims
- 1234US2018303799A1An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation MethodSHENZHEN SALUBRIS PHARM CO LTD·Filed 2016·Application pending·0 cites
- 1333US2016229891A1Salt of polypeptide vaccine, preparation method therefor, and pharmaceutical preparation comprising said saltSHENZHEN SALUBRIS PHARM CO LTD·Filed 2014·Application pending·0 cites
- 1430US10100039B2Allisartan isoproxil polymorph, its preparation method and pharmaceuticalSHENZHEN SALUBRIS PHARM CO LTD·Filed 2015·Granted Oct 16, 2018·0 cites·11 claims
- 1521US2017157095A1Allisartan isoproxil solid dispersion and pharmaceutical compositionSHENZHEN SALUBRIS PHARM CO LTD·Filed 2015·Application pending·0 cites
- 1619US2017157098A1Clopidogrel Hydrogen Sulfate Solid Preparation and Its Preparation MethodSHENZHEN SALUBRIS PHARM CO LTD·Filed 2016·Application pending·0 cites
- 1715US2017135989A1Allisartan isoproxil solid dispersion and pharmaceutical compositionSHENZHEN SALUBRIS PHARM CO LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHENZHEN SALUBRIS PHARM CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →